"Because of defendants' scheme to delay and suppress generic Lipitor competition, in whole or in part, plaintiffs have paid hundreds of millions of dollars more for atorvastatin calcium than they would have paid," according to the complaint, which seeks triple damages and other remedies.

Adding to all this, Pfizer has now been sued by five U.S. retailers (pharmacies) who accuse the company of monopolistic market practices. According to the lawsuit, Pfizer conspired to prevent generic versions of its blockbuster cholesterol drug Lipitor from entering the market. This was done to protect billions in profits while making sure patients did not have access to more affordable cholesterol drugs. Pfizer sells nearly $10 billion worth of Lipitor each year